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The Centers for Disease Control played a major role in sounding the first alarm about the morbidity and mortality associated with the use of prescription opioids [1] . Trend analyses from several states reported an alarming increase in opioid-related deaths [2] . In an effort to reduce the harm and diversion associated with opioids, states responded by passing laws targeting "pill mills" [3] or establishing dosage triggers, which required a mandatory pain consultation once a chronic pain patient had reached 120 mg morphine equivalent dose per day [4] . Not wanting to be left behind as the drug policy pendulum swung away from opioids, federal officials advocated for mandatory education of prescribers [5] and the investigation of patient advocacy groups and research organizations who had received funding from opioid manufacturers [6] .
While reducing the harm associated with opioids should always be of one of our highest priorities, this newest policy crusade against opioids lacks two necessary elements when creating any good public policy: balance and humility. The misuse and abuse of opioids have caused harm, but all efforts to reduce those harms must recognize the real need to ensure access and the positive role that opioids have in the daily lives of suffering patients. Secondly, any stakeholder, advocate, or researcherturned-advocate must also recognize that their model or preferred approach may be wrong as any action or inaction can lead to additional harm. This hubris and imbalance is not only evidenced by politicians who pander to a mobilized vocal minority about the drug abuse problem without giving any recognition to its complexity nor the positive role that opioid therapy has played in the lives of chronic pain patients [7] , but it also appears to be evident in published articles where physicians are portrayed more as advocates for one particular policy solution rather than detached researchers [8, 9] . Opioids remain one of many available therapies to treat the millions of Americans who are suffering in pain. The harm associated with drug abuse and opioids is serious and must certainly be addressed. But to champion one particular approach without regard to its potential or subsequent impact on pain patients is not only misguided and unbalanced; it may also suggest that it is more about the advocate than a particular program or intervention.
In the end, it appears that the pendulum has swung away from opioids [10, 11] , and the opioid train has left the station and abandoned some chronic pain patients on the platform [12, 13] . Perhaps another train will come along soon, a train where everyone has equal access, participation, and is filled with people who recognize the need for balance and realize that they could ultimately be wrong. Until that time, however, we will likely be left with state and national drug policies or proposals that fixate on opioid-related deaths, with little regard to legitimate patients [12, 14, 15] , while ignoring the hypocrisy of a national drug policy that supports the growth and sale of tobacco, a substance without any legitimate use, has not relieved suffering, and is linked to a staggering 443,000 deaths per year [16] . The root causes of opioidrelated deaths are many [17] , and there will never be a simple solution to reducing the harms associated with opioids while simultaneously ensuring their access. But efforts aimed at solving one problem without regard to the impact it will have on patients who rely on opioids to function are ultimately doomed to fail. Balanced policy interventions may not be perfect, but they are possible so long as these competing concerns are actively considered and addressed [14, [18] [19] [20] [21] .
